Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 18, 2009 - Issue 5
Submit an article Journal homepage
353
Views
18
CrossRef citations to date
0
Altmetric
Drug Evaluations

Spinal cord injury and neural repair: focus on neuroregenerative approaches for spinal cord injury

Darryl C Baptiste University Health Network, Toronto Western Hospital, Toronto Western Research Institute,Krembil Neuroscience Centre, Toronto, Ontario, Canada. +1 416 603 5364; +1 416 603 5745; [email protected]
, PhD,
Allyson Tighe University Health Network, Toronto Western Hospital, Toronto Western Research Institute, Krembil Neuroscience Centre, Toronto, Ontario, Canada
, MSc &
Michael G Fehlings University Health Network, Toronto Western Hospital, Toronto Western Research Institute, Krembil Neuroscience Centre, Toronto, Ontario, Canada; Department of Surgery and Division of Neurosurgery, University of Toronto, Toronto, Ontario, Canada
, MD PhD FRCSC
Pages 663-673 | Published online: 21 Apr 2009

Bibliography

  • Sekhon LH, Fehlings MG. Epidemiology, demographics, and pathophysiology of acute spinal cord injury. Spine 2001;26:S2-12
  • Anderson KD. Targeting recovery: priorities of the spinal cord-injured population. J Neurotrauma 2004;21:1371-83
  • Craig A, Tran Y, Middleton J. Psychological morbidity and spinal cord injury: a systematic review. Spinal Cord 2008
  • Tator CH, Fehlings MG. Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms. J Neurosurg 1991;75:15-26
  • Majno G, Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol 1995;146:3-15
  • Hockenbery D. Defining apoptosis. Am J Pathol 1995;146:16-19
  • Profyris C, Cheema SS, Zang D, et al. Degenerative and regenerative mechanisms governing spinal cord injury. Neurobiol Dis 2004;15:415-36
  • Moyse E, Segura S, Liard O, et al. Microenvironmental determinants of adult neural stem cell proliferation and lineage commitment in the healthy and injured central nervous system. Curr Stem Cell Res Ther 2008;3:163-84
  • Casha S, Yu W, Fehlings MG. Oligodendroglial apoptosis occurs along degenerating axons and is associated with FAS and p75 expression following spinal cord injury in the rat. Neuroscience 2001;103:203-18
  • Emery E, Aldana P, Bunge MB, et al. Apoptosis after traumatic human spinal cord injury. J Neurosurg 1998;89:911-20
  • Liu XZ, Xu XM, Hu R, et al. Neuronal and glial apoptosis after traumatic spinal cord injury. J Neurosci 1997;17:5395-406
  • Baumann N, Pham-Dinh D. Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol Rev 2001;81:871-927
  • Bracken MB, Shepard MJ, Holford TR, et al. Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury: 1-year follow up. Results of the third National Acute Spinal Cord Injury randomized controlled trial. J Neurosurg 1998;89:699-706
  • Bracken MB, Shepard MJ, Holford TR, et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 1997;277:1597-604
  • Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 1990;322:1405-11
  • Hall ED, Springer JE. Neuroprotection and acute spinal cord injury: a reappraisal. NeuroRx 2004;1:80-100
  • Geisler FH, Coleman WP, Grieco G, Poonian D. Recruitment and early treatment in a multicenter study of acute spinal cord injury. Spine 2001;26:S58-67
  • Geisler FH, Coleman WP, Grieco G, Poonian D. Measurements and recovery patterns in a multicenter study of acute spinal cord injury. Spine 2001;26:S68-86
  • Geisler FH, Coleman WP, Grieco G, Poonian D. The Sygen multicenter acute spinal cord injury study. Spine 2001;26:S87-98
  • Hurlbert RJ. Methylprednisolone for acute spinal cord injury: an inappropriate standard of care. J Neurosurg 2000;93:S1-7
  • Richardson PM, McGuinness UM, Aguayo AJ. Axons from CNS neurons regenerate into PNS grafts. Nature 1980;284:264-5
  • Reynolds BA, Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 1992;255:1707-10
  • Greenwood HL, Singer PA, Downey GP, et al. Regenerative medicine and the developing world. PLoS Med 2006;3:e381
  • Nomura H, Tator CH, Shoichet MS. Bioengineered strategies for spinal cord repair. J Neurotrauma 2006;23:496-507
  • Zhou L, Baumgartner BJ, Hill-Felberg SJ, et al. Neurotrophin-3 expressed in situ induces axonal plasticity in the adult injured spinal cord. J Neurosci 2003;23:1424-31
  • Blesch A, Tuszynski MH. Cellular GDNF delivery promotes growth of motor and dorsal column sensory axons after partial and complete spinal cord transections and induces remyelination. J Comp Neurol 2003;467:403-17
  • Schnell L, Schneider R, Kolbeck R, et al. Neurotrophin-3 enhances sprouting of corticospinal tract during development and after adult spinal cord lesion. Nature 1994;367:170-3
  • Eftekharpour E, Karimi-Abdolrezaee S, Wang J, et al. Myelination of congenitally dysmyelinated spinal cord axons by adult neural precursor cells results in formation of nodes of Ranvier and improved axonal conduction. J Neurosci 2007;27:3416-28
  • Karimi-Abdolrezaee S, Eftekharpour E, Wang J, et al. Delayed transplantation of adult neural precursor cells promotes remyelination and functional neurological recovery after spinal cord injury. J Neurosci 2006;26:3377-89
  • Wyndaele M, Wyndaele JJ. Incidence, prevalence and epidemiology of spinal cord injury: what learns a worldwide literature survey? Spinal Cord 2006;44:523-9
  • DeVivo MJ. Causes and costs of spinal cord injury in the United States. Spinal Cord 1997;35:809-13
  • National Center for Injury Prevention and Control: Traumatic Brain Injury Fact Sheet. Available from: http://www.cdc.gov/ncipc/tbi/TBI.htm [Last accessed 22 December 2008]
  • Whetten-Goldstein K, Sloan FA, Goldstein LB, Kulas ED. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998;4:419-25
  • Brown DL, Boden-Albala B, Langa KM, et al. Projected costs of ischemic stroke in the United States. Neurology 2006;67:1390-5
  • Mason C, Dunnill P. The strong financial case for regenerative medicine and the regen industry. Regen Med 2008;3:351-63
  • Hirtz D, Thurman DJ, Gwinn-Hardy K, et al. How common are the ‘common’ neurologic disorders? Neurology 2007;68:326-37
  • Jalink K, van Corven EJ, Hengeveld T, et al. Inhibition of lysophosphatidate- and thrombin-induced neurite retraction and neuronal cell rounding by ADP ribosylation of the small GTP-binding protein Rho. J Cell Biol 1994;126:801-10
  • Madura T, Yamashita T, Kubo T, et al. Activation of Rho in the injured axons following spinal cord injury. EMBO Rep 2004;5:412-17
  • Dergham P, Ellezam B, Essagian C, et al. Rho signaling pathway targeted to promote spinal cord repair. J Neurosci 2002;22:6570-7
  • Laufs U, Endres M, Stagliano N, et al. Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J Clin Invest 2000;106:15-24
  • Alseres Pharmaceuticals. Available from: http://www.alseres.com/about-us/index.asp [Last accessed 22 December 2008]
  • Philips H. Brainstorming. Neuron 2004;44(Suppl):2-5
  • Fehlings MG, Maurais G, Theodore N, et al. Results of a prospective, multicenter Phase I/IIa Clinical trial to evaluate safety and preliminary efficacy of a recombinant rho inhibitor (Cethrin) in severe acute spinal cord injury. J Neurosurg 2008;108:A861-2
  • Suzuki Y, Shibuya M, Satoh S, et al. A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage. Surg Neurol 2007;68:126-31
  • Suzuki Y, Shibuya M, Satoh S, et al. Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage: sub-analysis of the post-marketing surveillance study. Neurol Med Chir (Tokyo) 2008;48:241-7
  • Otsuka T, Ibuki C, Suzuki T, et al. Administration of the Rho-kinase inhibitor, fasudil, following nitroglycerin additionally dilates the site of coronary spasm in patients with vasospastic angina. Coron Artery Dis 2008;19:105-10
  • ClinicalTrials.gov. 2008. Available from: http://clinicaltrials.gov [Last accessed 22 December 2008]
  • Chen MS, Huber AB, van der Haar ME, et al. Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature 2000;403:434-9
  • Mukhopadhyay G, Doherty P, Walsh FS, et al. A novel role for myelin-associated glycoprotein as an inhibitor of axonal regeneration. Neuron 1994;13:757-67
  • Vourc'h P, Moreau T, Arbion F, et al. Oligodendrocyte myelin glycoprotein growth inhibition function requires its conserved leucine-rich repeat domain, not its glycosylphosphatidyl-inositol anchor. J Neurochem 2003;85:889-97
  • Niederost BP, Zimmermann DR, Schwab ME, Bandtlow CE. Bovine CNS myelin contains neurite growth-inhibitory activity associated with chondroitin sulfate proteoglycans. J Neurosci 1999;19:8979-89
  • Schori H, Shechter R, Shachar I, Schwartz M. Genetic manipulation of CD74 in mouse strains of different backgrounds can result in opposite responses to central nervous system injury. J Immunol 2007;178:163-71
  • Rapalino O, Lazarov-Spiegler O, Agranov E, et al. Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat Med 1998;4:814-21
  • Ibarra A, Hauben E, Butovsky O, Schwartz M. The therapeutic window after spinal cord injury can accommodate T cell-based vaccination and methylprednisolone in rats. Eur J Neurosci 2004;19:2984-90
  • Hauben E, Gothilf A, Cohen A, et al. Vaccination with dendritic cells pulsed with peptides of myelin basic protein promotes functional recovery from spinal cord injury. J Neurosci 2003;23:8808-19
  • Bomstein Y, Marder JB, Vitner K, et al. Features of skin-coincubated macrophages that promote recovery from spinal cord injury. J Neuroimmunol 2003;142:10-16
  • Knoller N, Auerbach G, Fulga V, et al. Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: phase I study results. J Neurosurg Spine 2005;3:173-81
  • Kigerl K, Popovich P. Drug evaluation: ProCord – a potential cell-based therapy for spinal cord injury. Drugs 2006;9:354-60
  • Fehlings MG. Complete cord injury. J Neurosurg Spine 2005;3:171-2
  • Rossignol S, Schwab M, Schwartz M, Fehlings MG. Spinal cord injury: time to move? J Neurosci 2007;27:11782-92
  • ProNeuron Biotechnologies Clinical Studies. 2009. Available from: http://www.proneuron.com/clinicalstudies/index.html [Last accessed 11 March 2009]
  • Pharmacoprojects. 2007. Available from: http://www.pharmaprojects.com/ [Last accessed 22 December 2008]
  • Griswold DE, Webb EF, Badger AM, et al. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo. J Pharmacol Exp Ther 1998;287:705-11
  • Yoshikawa M, Suzumura A, Tamaru T, et al. Effects of phosphodiesterase inhibitors on cytokine production by microglia. Mult Scler 1999;5:126-33
  • Beshay E, Croze F, Prud'homme GJ. The phosphodiesterase inhibitors pentoxifylline and rolipram suppress macrophage activation and nitric oxide production in vitro and in vivo. Clin Immunol 2001;98:272-9
  • Zhang B, Yang L, Konishi Y, et al. Suppressive effects of phosphodiesterase type IV inhibitors on rat cultured microglial cells: comparison with other types of cAMP-elevating agents. Neuropharmacology 2002;42:262-9
  • Sommer N, Martin R, McFarland HF, et al. Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease. J Neuroimmunol 1997;79:54-61
  • Block F, Schmidt W, Nolden-Koch M, Schwarz M. Rolipram reduces excitotoxic neuronal damage. Neuroreport 2001;12:1507-11
  • Chen RW, Williams AJ, Liao Z, et al. Broad spectrum neuroprotection profile of phosphodiesterase inhibitors as related to modulation of cell-cycle elements and caspase-3 activation. Neurosci Lett 2007;418:165-9
  • Bandtlow CE. Regeneration in the central nervous system. Exp Gerontol 2003;38:79-86
  • Gao Y, Deng K, Hou J, et al. Activated CREB is sufficient to overcome inhibitors in myelin and promote spinal axon regeneration in vivo. Neuron 2004;44:609-21
  • Hannila SS, Filbin MT. The role of cyclic AMP signaling in promoting axonal regeneration after spinal cord injury. Exp Neurol 2007;309:321-332
  • Otten U, Marz P, Heese K, et al. Cytokines and neurotrophins interact in normal and diseased states. Ann NY Acad Sci 2000;917:322-30
  • Hebenstreit GF, Fellerer K, Fichte K, et al. Rolipram in major depressive disorder: results of a double-blind comparative study with imipramine. Pharmacopsychiatry 1989;22:156-60
  • Nikulina E, Tidwell JL, Dai HN, et al. The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery. Proc Natl Acad Sci USA 2004;101:8786-90
  • Fournier AE, Grandpre T, Strittmatter SM. Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration. Nature 2001;409:341-6
  • Liu BP, Fournier A, Grandpre T, Strittmatter SM. Myelin-associated glycoprotein as a functional ligand for the Nogo-66 receptor. Science 2002;297:1190-3
  • Schnell L, Schwab ME. Axonal regeneration in the rat spinal cord produced by an antibody against myelin-associated neurite growth inhibitors. Nature 1990;343:269-72
  • Iaci JF, Vecchione AM, Zimber MP, Caggiano AO. Chondroitin sulfate proteoglycans in spinal cord contusion injury and the effects of chondroitinase treatment. J Neurotrauma 2007;24:1743-60
  • Massey JM, Amps J, Viapiano MS, et al. Increased chondroitin sulfate proteoglycan expression in denervated brainstem targets following spinal cord injury creates a barrier to axonal regeneration overcome by chondroitinase ABC and neurotrophin-3. Exp Neurol 2008;209:426-45
  • Barritt AW, Davies M, Marchand F, et al. Chondroitinase ABC promotes sprouting of intact and injured spinal systems after spinal cord injury. J Neurosci 2006;26:10856-67
  • Grimpe B, Silver J. A novel DNA enzyme reduces glycosaminoglycan chains in the glial scar and allows microtransplanted dorsal root ganglia axons to regenerate beyond lesions in the spinal cord. J Neurosci 2004;24:1393-7
  • Ikegami T, Nakamura M, Yamane J, et al. Chondroitinase ABC combined with neural stem/progenitor cell transplantation enhances graft cell migration and outgrowth of growth-associated protein-43-positive fibers after rat spinal cord injury. Eur J Neurosci 2005;22:3036-46
  • Fouad K, Schnell L, Bunge MB, et al. Combining Schwann cell bridges and olfactory-ensheathing glia grafts with chondroitinase promotes locomotor recovery after complete transection of the spinal cord. J Neurosci 2005;25:1169-78
  • Agnati LF, Fuxe K, Benfenati F, et al. Chronic ganglioside treatment counteracts the biochemical signs of dopamine receptor supersensitivity induced by chronic haloperidol treatment. Neurosci Lett 1983;40:293-7
  • Agnati LF, Fuxe K, Calza L, et al. Gangliosides increase the survival of lesioned nigral dopamine neurons and favour the recovery of dopaminergic synaptic function in striatum of rats by collateral sprouting. Acta Physiol Scand 1983;119:347-63
  • Fass B, Ramirez JJ. Effects of ganglioside treatments on lesion-induced behavioral impairments and sprouting in the CNS. J Neurosci Res 1984;12:445-58
  • Bose B, Osterholm JL, Kalia M. Ganglioside-induced regeneration and reestablishment of axonal continuity in spinal cord-transected rats. Neurosci Lett 1986;63:165-9
  • Geisler FH, Dorsey FC, Coleman WP. Recovery of motor function after spinal-cord injury–a randomized, placebo-controlled trial with GM-1 ganglioside. N Engl J Med 1991;324:1829-38
  • Pisano GP. Can science be a business? Lessons from biotech. Harv Bus Rev 2006;84:114-24,50

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.